Ixekizumab trough concentrations in psoriasis: Paving the way towards personalised therapy: A cohort study
Abstract Background Biologics for psoriasis demonstrate varying clinical outcome in real‐world practice, implying potential under‐ and overexposure. Objectives In this prospective cohort study we aimed to develop and validate an in‐house sandwich‐type enzyme‐linked immunosorbent assay (ELISA) for ix...
Saved in:
Main Authors: | Lisa Schots (Author), Rani Soenen (Author), Debby Thomas (Author), Annelies Stockman (Author), Erwin Dreesen (Author), Anke Eylenbosch (Author), Jo Lambert (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Demographics, Disease Characteristics, and Time to Effective Treatment of Patients with Psoriasis in the Ghent PsoPlus Cohort of 2021
by: Evelyn Meulewaeter, et al.
Published: (2024) -
Aging and nutrition. Paving the way to better health
by: Molina-Molina Emilio, et al.
Published: (2020) -
Erythrodermic psoriasis after discontinuation of ixekizumab
by: Kathryn Anne Potter, MD, et al.
Published: (2018) -
Toxoplasmosis in a patient receiving ixekizumab for psoriasis
by: Yolanka Lobo, BPhysio, MBBS, et al.
Published: (2020) -
Biomarkers in Psoriasis: The Future of Personalised Treatment
by: Bikash R. Kar, et al.
Published: (2024)